These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28118956)

  • 1. Design and synthesis of potent substrate-based inhibitors of the Trypanosoma cruzi dihydroorotate dehydrogenase.
    Inaoka DK; Iida M; Hashimoto S; Tabuchi T; Kuranaga T; Balogun EO; Honma T; Tanaka A; Harada S; Nara T; Kita K; Inoue M
    Bioorg Med Chem; 2017 Feb; 25(4):1465-1470. PubMed ID: 28118956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase from Y strain.
    Pinheiro MP; Iulek J; Cristina Nonato M
    Biochem Biophys Res Commun; 2008 May; 369(3):812-7. PubMed ID: 18302934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational study of the mechanism of half-reactions in class 1A dihydroorotate dehydrogenase from Trypanosoma cruzi.
    Silva Nde F; Lameira J; Alves CN; Martí S
    Phys Chem Chem Phys; 2013 Nov; 15(43):18863-71. PubMed ID: 24084894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modeling for anti-Chagas drug design using the fragment molecular orbital method.
    Yoshino R; Yasuo N; Inaoka DK; Hagiwara Y; Ohno K; Orita M; Inoue M; Shiba T; Harada S; Honma T; Balogun EO; da Rocha JR; Montanari CA; Kita K; Sekijima M
    PLoS One; 2015; 10(5):e0125829. PubMed ID: 25961853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory action of marine algae extracts on the Trypanosoma cruzi dihydroorotate dehydrogenase activity and on the protozoan growth in mammalian cells.
    Nara T; Kamei Y; Tsubouchi A; Annoura T; Hirota K; Iizumi K; Dohmoto Y; Ono T; Aoki T
    Parasitol Int; 2005 Mar; 54(1):59-64. PubMed ID: 15710552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery.
    Cheleski J; Rocha JR; Pinheiro MP; Wiggers HJ; da Silva AB; Nonato MC; Montanari CA
    Eur J Med Chem; 2010 Dec; 45(12):5899-909. PubMed ID: 20965617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic diversity and kinetic properties of Trypanosoma cruzi dihydroorotate dehydrogenase isoforms.
    Sariego I; Annoura T; Nara T; Hashimoto M; Tsubouchi A; Iizumi K; Makiuchi T; Murata E; Kita K; Aoki T
    Parasitol Int; 2006 Mar; 55(1):11-6. PubMed ID: 16172019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trypanosoma cruzi trans-sialidase as a drug target against Chagas disease (American trypanosomiasis).
    Miller BR; Roitberg AE
    Future Med Chem; 2013 Oct; 5(15):1889-900. PubMed ID: 24144418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel N,N-di-alkylnaphthoimidazolium derivative of β-lapachone impaired Trypanosoma cruzi mitochondrial electron transport system.
    Bombaça ACS; Silva LA; Chaves OA; da Silva LS; Barbosa JMC; da Silva AM; Ferreira ABB; Menna-Barreto RFS
    Biomed Pharmacother; 2021 Mar; 135():111186. PubMed ID: 33395606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structures of Trypanosoma cruzi dihydroorotate dehydrogenase complexed with substrates and products: atomic resolution insights into mechanisms of dihydroorotate oxidation and fumarate reduction.
    Inaoka DK; Sakamoto K; Shimizu H; Shiba T; Kurisu G; Nara T; Aoki T; Kita K; Harada S
    Biochemistry; 2008 Oct; 47(41):10881-91. PubMed ID: 18808149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in trans-sialidase inhibitors of Trypanosoma cruzi.
    Kashif M; Moreno-Herrera A; Lara-Ramirez EE; Ramírez-Moreno E; Bocanegra-García V; Ashfaq M; Rivera G
    J Drug Target; 2017 Jul; 25(6):485-498. PubMed ID: 28140698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents.
    Vyas VK; Variya B; Ghate MD
    Eur J Med Chem; 2014 Jul; 82():385-93. PubMed ID: 24929289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase.
    Zuccotto F; Zvelebil M; Brun R; Chowdhury SF; Di Lucrezia R; Leal I; Maes L; Ruiz-Perez LM; Gonzalez Pacanowska D; Gilbert IH
    Eur J Med Chem; 2001 May; 36(5):395-405. PubMed ID: 11451529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Design, Synthesis and Trypanocidal Activity of Dipeptidyl Nitriles as Cruzain Inhibitors.
    Avelar LA; Camilo CD; de Albuquerque S; Fernandes WB; Gonçalez C; Kenny PW; Leitão A; McKerrow JH; Montanari CA; Orozco EV; Ribeiro JF; Rocha JR; Rosini F; Saidel ME
    PLoS Negl Trop Dis; 2015; 9(7):e0003916. PubMed ID: 26173110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of dihydroorotate dehydrogenase as a relevant drug target for 1-hydroxyquinolones in Toxoplasma gondii.
    Hegewald J; Gross U; Bohne W
    Mol Biochem Parasitol; 2013 Jul; 190(1):6-15. PubMed ID: 23747278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, purification and crystallization of Trypanosoma cruzi dihydroorotate dehydrogenase complexed with orotate.
    Inaoka DK; Takashima E; Osanai A; Shimizu H; Nara T; Aoki T; Harada S; Kita K
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2005 Oct; 61(Pt 10):875-8. PubMed ID: 16511183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
    Hurt DE; Sutton AE; Clardy J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational and Investigative Study of Flavonoids Active Against Typanosoma cruzi and Leishmania spp.
    Ribeiro FF; Junior FJ; da Silva MS; Scotti MT; Scotti L
    Nat Prod Commun; 2015 Jun; 10(6):917-20. PubMed ID: 26197515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
    Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
    Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
    Palace-Berl F; Pasqualoto KF; Jorge SD; Zingales B; Zorzi RR; Silva MN; Ferreira AK; de Azevedo RA; Teixeira SF; Tavares LC
    Eur J Med Chem; 2015; 96():330-9. PubMed ID: 25899337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.